Use of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association
Why the study?
Oncology drugs can cause poorly understood adverse cardiovascular effects, and research is hampered by animal models failing to reflect human myocardial biology.
Design
Scientific statement
Authors
Discussion
Loading...
Member takes
Implication
Supports iPSC-CM adoption for oncologic cardiotoxicity screening; extends preclinical testing beyond animal models.
Structured PICO
P
Population
Preclinical models for cancer drug cardiotoxicity testing
I
Intervention
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)
C
Comparator
Whole-animal models
O
Outcome
Drug-induced cardiotoxicity (contractile and electrophysiological dysfunction, structural abnormalities)
This AHA scientific statement highlights the promise of human induced pluripotent stem cell-derived cardiomyocytes as an in vitro tool to overcome the limitations of animal models in predicting cancer drug cardiotoxicity.
Cite This Study
Gintant et al. (2019) conducted a review in Cancer drug cardiotoxicity. Human induced pluripotent stem cell-derived cardiomyocytes was evaluated. Human induced pluripotent stem cell-derived cardiomyocytes hold great promise as an in vitro tool for understanding and testing oncological drug-induced cardiotoxicity.